Current understanding of the role of complement in IgA nephropathy

Journal of the American Society of Nephrology

Volumn 26, Issue 7, 2015, Pages 1503-1512

  Maillard, Nicolas ^a,b   Wyatt, Robert J ^c   Julian, Bruce A ^a   Kiryluk, Krzysztof ^d   Gharavi, Ali ^d   Fremeaux Bacchi, Veronique ^e   Novak, Jan ^a  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITÉ JEAN MONNET   (France)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d Department of Medicine ^*  (United States)

^e CENTRE DE RECHERCHE DES CORDELIERS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C4D; COMPLEMENT FACTOR H; LECTIN; MANNAN BINDING LECTIN; SERINE PROTEINASE; IMMUNOGLOBULIN A;

ANTIGEN ANTIBODY COMPLEX; COMPLEMENT ACTIVATION; DISEASE MARKER; GENE DELETION; GENOME ANALYSIS; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY PARENCHYMA; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; COMPREHENSION; FEMALE; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; MALE; METABOLISM; PATHOPHYSIOLOGY; PROGNOSIS; RISK FACTOR; ROLE PLAYING; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; COMPREHENSION; FEMALE; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GLOMERULONEPHRITIS, IGA; HUMANS; IMMUNOGLOBULIN A; MALE; PROGNOSIS; RISK FACTORS; ROLE; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 84934766063     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2014101000     Document Type: Review

References (105)

1. Berger J, Hinglais N: Intercapillary deposits of IgA-IgG. J Urol Nephrol (Paris) 74: 694-695, 1968
2. Berthoux FC, Mohey H, Afiani A: Natural history of primary IgA nephropathy. Semin Nephrol 28: 4-9, 2008
3. Conley ME, Cooper MD, Michael AF: Selective deposition of immunoglobulin A1 in immunoglobulin A nephropathy, anaphylactoid purpura nephritis, and systemic lupus erythematosus. J Clin Invest 66: 1432-1436, 1980
4. Russell MW, Mestecky J, Julian BA, Galla JH: IgA-associated renal diseases: Antibodies to environmental antigens in sera and deposition of immunoglobulins and antigens in glomeruli. J Clin Immunol 6: 74-86, 1986
5. Jennette JC: The immunohistology of IgA nephropathy.AmJ KidneyDis 12: 348-352, 1988
6. Wyatt RJ, Julian BA: IgA nephropathy. N Engl J Med 368: 2402-2414, 2013
7. Suzuki H, Kiryluk K, Novak J,Moldoveanu Z, Herr AB, Renfrow MB, Wyatt RJ, Scolari F, Mestecky J, Gharavi AG, Julian BA: The pathophysiology of IgA nephropathy. J Am Soc Nephrol 22: 1795-1803, 2011
8. Suzuki H, Fan R, Zhang Z, Brown R, Hall S, Julian BA, Chatham WW, Suzuki Y, Wyatt RJ, Moldoveanu Z, Lee JY, Robinson J, Tomana M, Tomino Y,Mestecky J, Novak J: Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest 119: 1668-1677, 2009
9. Launay P, Grossetête B, Arcos-Fajardo M, Gaudin E, Torres SP, Beaudoin L, Patey-Mariaud de Serre N, Lehuen A, Monteiro RC: Fca receptor (CD89) mediates the development of immunoglobulin A (IgA) nephropathy (Berger's disease). Evidence for pathogenic soluble receptor-IgA complexes in patients and CD89 transgenic mice. J Exp Med 191: 1999-2009, 2000
10. Ricklin D, Hajishengallis G, Yang K, Lambris JD: Complement: A key system for immune surveillance and homeostasis. Nat Immunol 11: 785-797, 2010
11. Kemper C, Pangburn MK, Fishelson Z: Complement nomenclature 2014. Mol Immunol 61: 56-58, 2014
12. Sahu A, Lambris JD: Structure and biology of complement protein C3, a connecting link between innate and acquired immunity. Immunol Rev 180: 35-48, 2001
13. Roumenina LT, Loirat C, Dragon-Durey MA, Halbwachs-Mecarelli L, Sautes-Fridman C, Fremeaux-Bacchi V: Alternative complement pathway assessment in patients with atypical HUS. J Immunol Methods 365: 8-26, 2011
14. Kemper C, Atkinson JP, Hourcade DE: Properdin: Emerging roles of a patternrecognition molecule. Annu Rev Immunol 28: 131-155, 2010
15. Cybulsky AV, Takano T, Papillon J, McTavish AJ: Complement-induced phospholipase A2 activation in experimental membranous nephropathy. Kidney Int 57: 1052-1062, 2000
16. Nangaku M, Shankland SJ, Couser WG: Cellular response to injury in membranous nephropathy. J Am Soc Nephrol 16: 1195-1204, 2005
17. QiuW, Zhou J, Zhu G, Zhao D, He F, Zhang J, Lu Y, Yu T, Liu L, Wang Y: Sublytic C5b-9 triggers glomerular mesangial cell apoptosis via XAF1 gene activation mediated by p300-dependent IRF-1 acetylation. Cell Death Dis 5: e1176, 2014
18. Zhang J, Li Y, Shan K, Wang L, Qiu W, Lu Y, Zhao D, Zhu G, He F,Wang Y: Sublytic C5b-9 induces IL-6 and TGF-b1 production by glomerular mesangial cells in rat Thy-1 nephritis through p300-mediated C/EBPb acetylation. FASEB J 28: 1511-1525, 2014
19. Evans DJ,Williams DG, Peters DK, Sissons JG, Boulton-Jones JM, Ogg CS, Cameron JS, Hoffbrand BI: Glomerular deposition of properdin in Henoch-Schönlein syndrome and idiopathic focal nephritis. BMJ 3: 326-328, 1973
20. Floege J, Moura IC, DahaMR: New insights into the pathogenesis of IgA nephropathy. Semin Immunopathol 36: 431-442, 2014
21. Wyatt RJ: The complement system in IgA nephropathy and Henoch-Schönlein purpura: Functional and genetic aspects. Contrib Nephrol 104: 82-91, 1993
22. McCoy RC, Abramowsky CR, Tisher CC: IgA nephropathy.AmJ Pathol 76: 123-144, 1974
23. Miyazaki R, Kuroda M, Akiyama T, Otani I, Tofuku Y, Takeda R: Glomerular deposition and serum levels of complement control proteins in patients with IgA nephropathy. Clin Nephrol 21: 335-340, 1984
24. Rauterberg EW, Lieberknecht HM, Wingen AM, Ritz E: Complement membrane attack (MAC) in idiopathic IgA-glomerulonephritis. Kidney Int 31: 820-829, 1987
25. Tomino Y, Sakai H, Nomoto Y, Endoh M, Arimori S, Fujita T: Deposition of C4-binding protein and beta 1H globulin in kidneys of patients with IgA nephropathy. Tokai J Exp Clin Med 6: 217-222, 1981
26. Lagrue G, Branellec A, Intrator L, Moisy M, Sobel A: Measurements of serum C3d in primitive chronic glomerular nephropathies. Nouv Presse Med 8: 1153-1156, 1979
27. Sølling J: Circulating immune complexes and complement breakdown product C3d in glomerulonephritis and kidney transplantation. Acta Pathol Microbiol Immunol Scand [C] 92C: 213-220, 1984
28. Wyatt RJ, Kanayama Y, Julian BA, Negoro N, Sugimoto S, Hudson EC, Curd JG: Complement activation in IgA nephropathy. Kidney Int 31: 1019-1023, 1987
29. Zwirner J, Burg M, Schulze M, Brunkhorst R, Götze O, Koch KM, Floege J: Activated complement C3: A potentially novel predictor of progressive IgA nephropathy. Kidney Int 51: 1257-1264, 1997
30. Wyatt RJ, Julian BA: Activation of complement in IgA nephropathy. AmJ Kidney Dis 12: 437-442, 1988
31. Tanaka C, Suhara Y, Kikkawa Y: Circulating immune complexes and complement breakdown products in childhood IgA nephropathy. Nippon Jinzo Gakkai Shi 33: 709-717, 1991
32. Hiemstra PS, Gorter A, Stuurman ME, Van Es LA, Daha MR: Activation of the alternative pathway of complement by human serum IgA. Eur J Immunol 17: 321-326, 1987
33. Roos A, Bouwman LH, vanGijlswijk-Janssen DJ, Faber-Krol MC, Stahl GL, Daha MR: Human IgA activates the complement systemvia themannan-binding lectin pathway. J Immunol 167: 2861-2868, 2001
34. Russell MW, Reinholdt J, Kilian M: Antiinflammatory activity of human IgA antibodies and their Faba fragments: Inhibition of IgG-mediated complement activation. Eur J Immunol 19: 2243-2249, 1989
35. Russell MW, Mansa B: Complement-fixing properties of human IgA antibodies. Alternative pathway complement activation by plastic-bound, but not specific antigenbound, IgA. Scand J Immunol 30: 175-183, 1989
36. Daha NA, Banda NK, Roos A, Beurskens FJ, Bakker JM, Daha MR, Trouw LA: Complement activation by (auto-) antibodies. Mol Immunol 48: 1656-1665, 2011
37. Endo M, Ohi H, Ohsawa I, Fujita T, Matsushita M, Fujita T: Glomerular deposition of mannose-binding lectin (MBL) indicates a novel mechanism of complement activation in IgA nephropathy. Nephrol Dial Transplant 13: 1984-1990, 1998
38. Hisano S, Matsushita M, Fujita T, Endo Y, Takebayashi S: Mesangial IgA2 deposits and lectin pathway-mediated complement activation in IgA glomerulonephritis. Am J Kidney Dis 38: 1082-1088, 2001
39. Matsuda M, Shikata K, Wada J, Sugimoto H, Shikata Y,Kawasaki T,MakinoH:Deposition of mannan binding protein and mannan binding protein-mediated complement activation in the glomeruli of patients with IgA nephropathy. Nephron 80: 408-413, 1998
40. Roos A, Rastaldi MP, Calvaresi N, Oortwijn BD, Schlagwein N, van Gijlswijk-Janssen DJ, Stahl GL, Matsushita M, Fujita T, van Kooten C, Daha MR: Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol 17: 1724-1734, 2006
41. D'Amico G, Imbasciati E, Di Belgioioso GB, Bertoli S, Fogazzi G, Ferrario F, Fellin G, Ragni A, Colasanti G,Minetti L, Ponticelli C: Idiopathic IgA mesangial nephropathy. Clinical and histological study of 374 patients. Medicine (Baltimore) 64: 49-60, 1985
42. Lee HJ, Choi SY, Jeong KH, Sung JY, Moon SK, Moon JY, Lee SH, Lee TW, Ihm CG: Association of C1q deposition with renal outcomes in IgA nephropathy. ClinNephrol 80: 98-104, 2013
43. Miyamoto H, Yoshioka K, Takemura T, Akano N, Maki S: Immunohistochemical study of the membrane attack complex of complement in IgA nephropathy. Virchows Arch A Pathol Anat Histopathol 413: 77-86, 1988
44. Onda K,Ohsawa I,Ohi H, TamanoM, Mano S, Wakabayashi M, Toki A, Horikoshi S, Fujita T, Tomino Y: Excretion of complement proteins and its activation marker C5b-9 in IgA nephropathy in relation to renal function. BMC Nephrol 12: 64, 2011
45. Rosenblad T, Rebetz J, Johansson M, Békássy Z, Sartz L, Karpman D: Eculizumab treatment for rescue of renal function in IgA nephropathy. Pediatr Nephrol 29: 2225-2228, 2014
46. Wyatt RJ, Julian BA, Galla JH: Properdin deficiency with IgA nephropathy. N Engl J Med 305: 1097, 1981
47. Wyatt RJ, Julian BA, Weinstein A, Rothfield NF, McLean RH: Partial H (beta 1H) deficiency and glomerulonephritis in two families. J Clin Immunol 2: 110-117, 1982
48. Wyatt RJ, Schneider PD, Alpers CE, Hudson EC, Julian BA: C4B deficiency in two siblings with IgA nephropathy. Am J Kidney Dis 15: 66-71, 1990
49. EdeyM, Strain L,Ward R, Ahmed S, Thomas T, Goodship TH: Is complement factor H a susceptibility factor for IgA nephropathy? Mol Immunol 46: 1405-1408, 2009
50. El Karoui K, Hill GS, Karras A, Jacquot C, Moulonguet L, Kourilsky O, Frémeaux-Bacchi V, Delahousse M, Duong Van Huyen JP, Loupy A, Bruneval P, Nochy D: A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy. J Am Soc Nephrol 23: 137-148, 2012
51. Gharavi AG, Kiryluk K, Choi M, Li Y, Hou P, Xie J, Sanna-Cherchi S,Men CJ, Julian BA, Wyatt RJ,Novak J, He JC,Wang H, Lv J, Zhu L, Wang W, Wang Z, Yasuno K, Gunel M, Mane S, Umlauf S, Tikhonova I, Beerman I, Savoldi S, Magistroni R, Ghiggeri GM, Bodria M, Lugani F, Ravani P, Ponticelli C, Allegri L, Boscutti G, Frasca G, Amore A, Peruzzi L, Coppo R, Izzi C, Viola BF, Prati E, Salvadori M, Mignani R, Gesualdo L, Bertinetto F,Mesiano P, Amoroso A, Scolari F, Chen N, Zhang H, Lifton RP: Genomewide association study identifies susceptibility loci for IgA nephropathy. Nat Genet 43: 321-327, 2011
52. Kiryluk K, Novak J: The genetics and immunobiology of IgA nephropathy. J Clin Invest 124: 2325-2332, 2014
53. Kiryluk K, Li Y, Sanna-Cherchi S, Rohanizadegan M, Suzuki H, Eitner F, Snyder HJ, Choi M, Hou P, Scolari F, Izzi C, GiganteM, Gesualdo L, Savoldi S,Amoroso A, Cusi D, Zamboli P, Julian BA, Novak J, Wyatt RJ, Mucha K, Perola M, Kristiansson K, Viktorin A, Magnusson PK, Thorleifsson G, Thorsteinsdottir U, Stefansson K, Boland A, Metzger M, Thibaudin L, Wanner C, Jager KJ,Goto S,Maixnerova D, Karnib HH, Nagy J, Panzer U, Xie J, Chen N, Tesar V, Narita I, Berthoux F, Floege J, Stengel B, Zhang H, Lifton RP, Gharavi AG: Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis. PLoS Genet 8: e1002765, 2012
54. Kiryluk K, Li Y, Scolari F, Sanna-Cherchi S, Choi M, Verbitsky M, Fasel D, Lata S, Prakash S, Shapiro S, Fischman C, Snyder HJ, Appel G, Izzi C, Viola BF, Dallera N, Del Vecchio L, Barlassina C, Salvi E, Bertinetto FE, Amoroso A, Savoldi S, Rocchietti M, Amore A, Peruzzi L, Coppo R, Salvadori M, Ravani P,Magistroni R, GhiggeriGM, Caridi G, BodriaM, Lugani F, Allegri L,DelsanteM, Maiorana M, Magnano A, Frasca G, Boer E, Boscutti G, Ponticelli C, Mignani R, Marcantoni C, Di Landro D, Santoro D, Pani A, Polci R, Feriozzi S, Chicca S, Galliani M, Gigante M, Gesualdo L, Zamboli P, Battaglia GG, Garozzo M, Maixnerová D, Tesar V, Eitner F, Rauen T, FloegeJ,Kovacs T, Nagy J, Mucha K, Pączek L, Zaniew M, Mizerska-Wasiak M, Roszkowska-Blaim M, Pawlaczyk K, Gale D, Barratt J, Thibaudin L, Berthoux F, Canaud G, Boland A, MetzgerM, Panzer U, Suzuki H, Goto S, Narita I, Caliskan Y, Xie J, Hou P, Chen N, Zhang H, Wyatt RJ, Novak J, Julian BA, Feehally J, Stengel B, Cusi D, Lifton RP, Gharavi AG: Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet 46: 1187-1196, 2014
55. Zhu L, Zhai YL, Wang FM, Hou P, Lv JC, Xu DM, Shi SF, Liu LJ, Yu F, ZhaoMH, Novak J, Gharavi AG, Zhang H: Variants in complement factor H and complement factor H-related protein genes, CFHR3 and CFHR1, affect complement activation in IgA nephropathy [published online ahead of print September 9, 2014]. J Am Soc Nephrol doi: ASN.2014010096
56. Holmes LV, Strain L, Staniforth SJ, Moore I, Marchbank K, Kavanagh D, Goodship JA, Cordell HJ, Goodship TH: Determining the population frequency of the CFHR3/CFHR1 deletion at 1q32. PLoS ONE 8: e60352, 2013
57. Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaimé F, Dragon-Durey MA, Ngo S, Moulin B, Servais A, Provot F, Rostaing L, Burtey S, Niaudet P, Deschênes G, Lebranchu Y, Zuber J, Loirat C: Genetics and outcome of atypical hemolytic uremic syndrome: A nationwide French series comparing children and adults. Clin J Am Soc Nephrol 8: 554-562, 2013
58. Skerka C, Chen Q, Fremeaux-Bacchi V, Roumenina LT: Complement factor H related proteins (CFHRs). Mol Immunol 56: 170-180, 2013
59. Tortajada A, Yébenes H, Abarrategui-Garrido C, Anter J, García-Fernández JM, Martínez-Barricarte R, Alba-Domínguez M, Malik TH, Bedoya R, Cabrera Pérez R, López Trascasa M, Pickering MC, Harris CL, Sánchez-Corral P, Llorca O, Rodríguez de Córdoba S: C3 glomerulopathy-associated CFHR1mutation alters FHR oligomerization and complement regulation. J Clin Invest 123: 2434-2446, 2013
60. Goicoechea de Jorge E, Caesar JJ,Malik TH, PatelM,ColledgeM, JohnsonS,Hakobyan S, Morgan BP, Harris CL, PickeringMC, Lea SM: Dimerization of complement factor H-related proteinsmodulates complement activation in vivo. Proc Natl Acad Sci U S A 110: 4685-4690, 2013
61. Timmann C, LeippeM, Horstmann RD: Two major serum components antigenically related to complement factor H are different glycosylation forms of a single protein with no factor H-like complement regulatory functions. J Immunol 146: 1265-1270, 1991
62. Hellwage J, Jokiranta TS, Koistinen V, Vaarala O, Meri S, Zipfel PF: Functional properties of complement factor H-related proteins FHR-3 and FHR-4: Binding to the C3d region of C3b and differential regulation by heparin. FEBS Lett 462: 345-352, 1999
63. Fritsche LG, Lauer N, Hartmann A, Stippa S, Keilhauer CN, Oppermann M, Pandey MK, Köhl J, Zipfel PF, Weber BH, Skerka C: An imbalance of human complement regulatory proteins CFHR1, CFHR3 and factor H influences risk for age-related macular degeneration (AMD). Hum Mol Genet 19: 4694-4704, 2010
64. Heinen S, Hartmann A, Lauer N, Wiehl U, Dahse HM, Schirmer S, Gropp K, Enghardt T, Wallich R, Hälbich S, Mihlan M, Schlötzer-Schrehardt U, Zipfel PF, Skerka C: Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation. Blood 114: 2439-2447, 2009
65. Hageman GS, Hancox LS, Taiber AJ, Gehrs KM, Anderson DH, Johnson LV, RadekeMJ, Kavanagh D, Richards A, Atkinson J,Meri S, Bergeron J, Zernant J, Merriam J, Gold B, Allikmets R, Dean M; AMD Clinical Study Group: Extended haplotypes in the complement factor H (CFH) and CFH-related (CFHR) family of genes protect against agerelated macular degeneration: Characterization, ethnic distribution and evolutionary implications. Ann Med 38: 592-604, 2006
66. Kubista KE, Tosakulwong N, Wu Y, Ryu E, Roeder JL, Hecker LA, Baratz KH, Brown WL, Edwards AO: Copy number variation in the complement factorH-related genes and age-related macular degeneration. Mol Vis 17: 2080-2092, 2011
67. AnsariM,McKeigue PM, Skerka C,Hayward C, Rudan I, Vitart V, Polasek O, Armbrecht AM, Yates JR, Vatavuk Z, Bencic G, Kolcic I, Oostra BA, Van Duijn CM, Campbell S, Stanton CM, Huffman J, Shu X, Khan JC, Shahid H, Harding SP, Bishop PN, Deary IJ, Moore AT, Dhillon B, Rudan P, Zipfel PF, Sim RB, Hastie ND, Campbell H,Wright AF: Genetic influences on plasma CFH and CFHR1 concentrations and their role in susceptibility to age-related macular degeneration. Hum Mol Genet 22: 4857-4869, 2013
68. Moore I, Strain L, Pappworth I, Kavanagh D, Barlow PN, Herbert AP, Schmidt CQ, Staniforth SJ, Holmes LV, Ward R, Morgan L,Goodship TH,Marchbank KJ: Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and withmutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood 115: 379-387, 2010
69. Józsi M, Licht C, Strobel S, Zipfel SL, Richter H, Heinen S, Zipfel PF, Skerka C: Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood 111: 1512-1514, 2008
70. Józsi M, Strobel S, Dahse HM, Liu WS, Hoyer PF, Oppermann M, Skerka C, Zipfel PF: Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome. Blood 110: 1516-1518, 2007
71. Dragon-Durey MA, Loirat C, Cloarec S, Macher MA, Blouin J, Nivet H, Weiss L, Fridman WH, Frémeaux-Bacchi V: Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 16: 555-563, 2005
72. Abarrategui-Garrido C, Martínez-Barricarte R, López-Trascasa M, de Córdoba SR, Sánchez-Corral P: Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome. Blood 114: 4261-4271, 2009
73. Richards A, Buddles MR, Donne RL, Kaplan BS, Kirk E, Venning MC, Tielemans CL, Goodship JA, Goodship TH: Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition. Am J Hum Genet 68: 485-490, 2001
74. Pérez-Caballero D, González-Rubio C, Gallardo ME, Vera M, López-Trascasa M, Rodríguez de Córdoba S, Sánchez-Corral P: Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome. Am J Hum Genet 68: 478-484, 2001
75. Zhao J, Wu H, Khosravi M, Cui H, Qian X, Kelly JA, Kaufman KM, Langefeld CD, Williams AH, Comeau ME, Ziegler JT, Marion MC, Adler A, Glenn SB, Alarcón-Riquelme ME, Pons-Estel BA, Harley JB, Bae SC, Bang SY, Cho SK, Jacob CO, Vyse TJ, Niewold TB, Gaffney PM, Moser KL, Kimberly RP, Edberg JC, Brown EE, Alarcon GS, Petri MA, Ramsey-Goldman R, Vilá LM, Reveille JD, James JA, Gilkeson GS, Kamen DL, Freedman BI, Anaya JM, Merrill JT, Criswell LA, Scofield RH, Stevens AM, Guthridge JM, Chang DM, Song YW, Park JA, Lee EY, Boackle SA, Grossman JM, Hahn BH, Goodship TH, Cantor RM, Yu CY, Shen N, Tsao BP; BIOLUPUS Network-GENLES Network: Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility. PLoS Genet 7: e1002079, 2011
76. Murphy B, Georgiou T, Machet D, Hill P, McRae J: Factor H-related protein-5: A novel component of human glomerular immune deposits. Am J Kidney Dis 39: 24-27, 2002
77. Czerkinsky C, Koopman WJ, Jackson S, Collins JE, Crago SS, Schrohenloher RE, Julian BA, Galla JH, Mestecky J: Circulating immune complexes and immunoglobulin A rheumatoid factor in patients with mesangial immunoglobulin A nephropathies. J Clin Invest 77: 1931-1938, 1986
78. van Es LA, van den Wall Bake AW, Valentijn RM, Daha MR: Composition of IgA-containing circulating immune complexes in IgA nephropathy. Am J Kidney Dis 12: 397-401, 1988
79. Yanagihara T, Brown R, Hall S, Moldoveanu Z, Goepfert A, Tomana M, Julian BA, Mestecky J, Novak J: In vitro-generated immune complexes containing galactosedeficient IgA1 stimulate proliferation of mesangial cells. Res Immunol 2: 166-172, 2012
80. Suzuki Y, Matsuzaki K, Suzuki H, Okazaki K, Yanagawa H, Ieiri N, Sato M, Sato T, Taguma Y, Matsuoka J, Horikoshi S, Novak J, Hotta O, Tomino Y: Serum levels of galactose-deficient immunoglobulin (Ig) A1 and related immune complex are associated with disease activity of IgA nephropathy. Clin Exp Nephrol 18: 770-777, 2014
81. Maillard N, Boerma L, Hall SD, Huang ZQ, Mrug M, Moldoveanu Z, Julian BA, Renfrow MB,Novak J: Proteomic analysis of engineered IgA1-IgG immune complexes reveals association with activated complement C3. J Am Soc Nephrol 24: 490A, 2013
82. Pickering MC, D'Agati VD, Nester CM, Smith RJ, Haas M, Appel GB, Alpers CE, Bajema IM, Bedrosian C, BraunM, Doyle M, Fakhouri F, Fervenza FC, Fogo AB, Frémeaux-Bacchi V, Gale DP, Goicoechea de Jorge E, Griffin G, Harris CL, Holers VM, Johnson S, Lavin PJ, Medjeral-Thomas N, PaulMorgan B, Nast CC, Noel LH, Peters DK, Rodríguez de Córdoba S, Servais A, Sethi S, Song WC, Tamburini P, Thurman JM, ZavrosM,Cook HT: C3 glomerulopathy:Consensus report. Kidney Int 84: 1079-1089, 2013
83. Servais A, Noël LH, Frémeaux-Bacchi V, Lesavre P: C3 glomerulopathy. Contrib Nephrol 181: 185-193, 2013
84. Servais A, Frémeaux-Bacchi V, Lequintrec M, Salomon R, Blouin J, Knebelmann B, Grünfeld JP, Lesavre P,Noël LH, Fakhouri F: Primary glomerulonephritiswith isolatedC3 deposits: A new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet 44: 193-199, 2007
85. Barbour TD, Pickering MC, Cook HT: Recent insights into C3 glomerulopathy. Nephrol Dial Transplant 28: 1685-1693, 2013
86. van den Dobbelsteen MEA, Verhasselt V, Kaashoek JGJ, Timmerman JJ, Schroeijers WEM, Verweij CL, van derWoude FJ, van Es LA, Daha MR: Regulation of C3 and factor H synthesis of human glomerular mesangial cells by IL-1 and interferon-gamma. Clin Exp Immunol 95: 173-180, 1994
87. Wan JX, Fukuda N, Endo M, Tahira Y, Yao EH, Matsuda H, Ueno T, Matsumoto K: Complement 3 is involved in changing the phenotype of human glomerular mesangial cells. J Cell Physiol 213: 495-501, 2007
88. Schmitt R, Stahl AL, Olin AI, Kristoffersson AC, Rebetz J, Novak J, Lindahl G, Karpman D: The combined role of galactosedeficient IgA1 and streptococcal IgA-binding M protein in inducing IL-6 and C3 secretion from human mesangial cells: Implications for IgA nephropathy. J Immunol 193: 317-326, 2014
89. Cosio FG, Shibata T, Rovin BH, Birmingham DJ: Effects of complement activation products on the synthesis of decay accelerating factor and membrane cofactor protein by human mesangial cells. Kidney Int 46: 986-992, 1994
90. Abe K, Miyazaki M, Koji T, Furusu A, Ozono Y, Harada T, Sakai H, Nakane PK, Kohno S: Expression of decay accelerating factor mRNA and complement C3 mRNA in human diseased kidney. Kidney Int 54: 120-130, 1998
91. Braun MC, Reins RY, Li TB, Hollmann TJ, Dutta R, Rick WA, Teng BB, Ke B: Renal expression of the C3a receptor and functional responses of primary human proximal tubular epithelial cells. J Immunol 173: 4190-4196, 2004
92. Komatsu H, Fujimoto S, Hara S, Sato Y, Yamada K, Eto T: Relationship between serum IgA/C3 ratio and progression of IgA nephropathy. Intern Med 43: 1023-1028, 2004
93. Zhang J, Wang C, Tang Y, Peng H, Ye ZC, Li CC, Lou TQ: Serum immunoglobulin A/C3 ratio predicts progression of immunoglobulin A nephropathy. Nephrology (Carlton) 18: 125-131, 2013
94. Kim SJ, Koo HM, Lim BJ, Oh HJ, Yoo DE, Shin DH, Lee MJ, Doh FM, Park JT, Yoo TH, Kang SW, Choi KH, Jeong HJ, Han SH: Decreased circulating C3 levels and mesangial C3 deposition predict renal outcome in patients with IgA nephropathy. PLoS ONE 7: e40495, 2012
95. Onda K, Ohi H, Tamano M, Ohsawa I, Wakabayashi M, Horikoshi S, Fujita T, Tomino Y: Hypercomplementemia in adult patients with IgA nephropathy. J Clin Lab Anal 21: 77-84, 2007
96. Zhang JJ, Jiang L, Liu G,Wang SX, ZouWZ, Zhang H, Zhao MH: Levels of urinary complement factor H in patients with IgA nephropathy are closely associated with disease activity. Scand J Immunol 69: 457-464, 2009
97. Cattran DC, Coppo R, Cook HT, Feehally J, Roberts IS, Troyanov S, Alpers CE,Amore A, Barratt J, Berthoux F, Bonsib S, Bruijn JA, D'Agati V, D'Amico G, Emancipator S, Emma F, Ferrario F, Fervenza FC, Florquin S, Fogo A, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hogg RJ, Hsu SI, Jennette JC, Joh K, Julian BA, Kawamura T, Lai FM, Leung CB, Li LS, Li PK, Liu ZH, Mackinnon B, Mezzano S, Schena FP, Tomino Y, Walker PD,WangH,Weening JJ, Yoshikawa N, Zhang H; Working Group of the International IgA Nephropathy Network and the Renal Pathology Society: The Oxford classification of IgA nephropathy: Rationale, clinicopathological correlations, and classification. Kidney Int 76: 534-545, 2009
98. Roberts IS, Cook HT, Troyanov S, Alpers CE, Amore A, Barratt J, Berthoux F, Bonsib S, Bruijn JA, Cattran DC, Coppo R, D'Agati V, D'Amico G, Emancipator S, Emma F, Feehally J, Ferrario F, Fervenza FC, Florquin S, Fogo A, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hogg RJ, Hsu SI, Jennette JC, Joh K, Julian BA, Kawamura T, Lai FM, Li LS, Li PK, Liu ZH, Mackinnon B, Mezzano S, Schena FP, Tomino Y, Walker PD, Wang H, Weening JJ, Yoshikawa N, Zhang H; Working Group of the International IgA Nephropathy Network and the Renal Pathology Society: The Oxford classification of IgA nephropathy: Pathology definitions, correlations, and reproducibility. Kidney Int 76: 546-556, 2009
99. Varis J, Rantala I, Pasternack A, Oksa H, Jäntti M, Paunu ES, Pirhonen R: Immunoglobulin and complement deposition in glomeruli of 756 subjects who had committed suicide or met with a violent death. J Clin Pathol 46: 607-610, 1993
100. Nasri H, Sajjadieh S, Mardani S, Momeni A, Merikhi A, Madihi Y, Ghiessari A, Emami Naieni A: Correlation of immunostaining findings with demographic data and variables of Oxford classification in IgA nephropathy. J Nephropathol 2: 190-195, 2013
101. Nakagawa H, Suzuki S, Haneda M, Gejyo F, Kikkawa R: Significance of glomerular deposition of C3c and C3d in IgA nephropathy. Am J Nephrol 20: 122-128, 2000
102. Espinosa M, Ortega R, Sánchez M, Segarra A, Salcedo MT, González F, Camacho R, Valdivia MA, Cabrera R, López K, Pinedo F, Gutierrez E, Valera A, Leon M, Cobo MA, Rodriguez R, Ballarín J, Arce Y, García B, Muñoz MD, Praga M; Spanish Group for Study of Glomerular Diseases (GLOSEN): Association of C4d deposition with clinical outcomes in IgA nephropathy. Clin J Am Soc Nephrol 9: 897-904, 2014
103. Maeng YI, Kim MK, Park JB, Cho CH, Oh HK, Sung WJ, Park KK: Glomerular and tubular C4d depositions in IgA nephropathy: Relations with histopathology and with albuminuria. Int J Clin Exp Pathol 6: 904-910, 2013
104. Vuong MT, Hahn-Zoric M, Lundberg S, Gunnarsson I, van Kooten C, Wramner L, Seddighzadeh M, Fernström A, Hanson LA, Do LT, Jacobson SH, Padyukov L: Association of soluble CD89 levels with disease progression but not susceptibility in IgA nephropathy. Kidney Int 78: 1281-1287, 2010
105. Berthelot L, Papista C, Maciel TT, Biarnes-Pelicot M, Tissandie E, Wang PH, Tamouza H, JaminA, Bex-Coudrat J,Gestin A, Boumediene A, Arcos-FajardoM, England P, Pillebout E, Walker F, Daugas E, Vrtosvnik F, Flamant M, Benhamou M, Cogné M, Moura IC, Monteiro RC: Transglutaminase is essential for IgA nephropathy development acting through IgA receptors. J Exp Med 209: 793-806, 2012